2015 Volume 3 Issue 1 Pages 31-35
Many factors cause dyslipidemia after kidney transplantation. Low density lipoprotein cholesterol (LDL-C) has been focused to reduce cardiovasucular disease (CVD), but residual risk factors such as triglyceride (TG), remnants or small dense LDL-C are also important to reduce CVD. Then, we investigated whether statin usage reduce residual risks of CVD in kidney transplant recipients. This study is a cross-sectional method applied at a single center. Fourhundred and sixty kidney transplant recipients (male 266, female 194) in more than six months after transplantation were enrolled. Patients with statin were in group 1 and patients without statin were in group 2. TG, Remnantlike particle-cholesterol (RLP-C), non-HDL-C and LDL-C/apoB were compared in 2 groups with or without statin usage. Mean age (years) was 50.38±13.42, mean vintage after kidney transplantation (months) was 70.42±78.29, and mean BMI (kg/m2) was 21.88±3.77. Due to administration of statins, there was no significant difference in LDL-C and eGFR (estimated glomerular filtration rate) between 2 groups. The number of patients with diabetic nephropathy were also similar. However, TG and RLP-C were higher and LDL-C/apoB was lower in group 1 despite of statin treatment. This study showed that LDL-C could be controlled easily by statin use, but TG, RLP-C, and LDL-C/apoB remained uncontrolled. Conclusion is that residual risk factors are not improved regardless of statin use. Intervention to reduce these factors is needed.
